1 period filed. Holdings below describe the selected month only.
NPORT-P · filed 2026-05-20
as filed
N-PORT Item C.4.b
N-PORT Item C.4.a
No share classes in the SEC snapshot.
2,774 filed series have no class in company_tickers_mf.json, so no ticker can be reached for them.
68 positions in this filing
| Issuer↕ | In master | CUSIP / ISIN | Asset | Balance↕ | Value↕ | Weight▼ | Country |
|---|---|---|---|---|---|---|---|
| BioAge Labs Inc. BioAge Labs, Inc. | BIOA | 09077V100 US09077V1008 | EC CORP | 6,693 NS |
| 1.151% |
| US |
| Maze Therapeutics Inc Maze Therapeutics, Inc. | MAZE | 578784100 US5787841007 | EC CORP | 3,713 NS | $110.8K | 1.090% | US |
| AGPXX Invesco Government & Agency Portfolio | — | 825252897 US8252528851 | STIV RF | 107,993.25 NS | $108.0K | 1.062% | US |
| Septerna Inc. Septerna, Inc. | SEPN | 81734D104 US81734D1046 | EC CORP | 4,081 NS | $98.1K | 0.964% | US |
| Wave Life Sciences Ltd. WaVe Life Sciences Ltd. | — | Y95308105 SG9999014716 | EC CORP | 13,302 NS | $96.4K | 0.948% | US |
| Zevra Therapeutics Inc Zevra Therapeutics, Inc. | ZVRA | 488445206 US4884452065 | EC CORP | 10,307 NS | $96.1K | 0.945% | US |
| Fulcrum Therapeutics Inc Fulcrum Therapeutics, Inc. | FULC | 359616109 US3596161097 | EC CORP | 11,666 NS | $89.5K | 0.880% | US |
| N/A SOCIETE' GENERALE 3.54 , 4/01/2026 | — | — — | RA CORP | 88,000 PA | $88.0K | 0.865% | US |
| Aquestive Therapeutics Inc Aquestive Therapeutics, Inc. | AQST | 03843E104 US03843E1047 | EC CORP | 19,045 NS | $79.0K | 0.777% | US |
| LB Pharmaceuticals Inc. LB Pharmaceuticals, Inc. | LBRX | 50180M108 US50180M1080 | EC CORP | 2,830 NS | $69.8K | 0.686% | US |
| N/A CF Secured 3.54 , 4/01/2026 | — | — — | RA CORP | 63,000 PA | $63.0K | 0.620% | US |
| Alto Neuroscience Inc | ANRO | 02157Q109 US02157Q1094 | EC CORP | 2,325 NS | $52.3K | 0.514% | US |
| N/A HSBC SECURITIES (USA), INC. B 3.5 , 4/01/2026 | — | — — | RA CORP | 44,000 PA | $44.0K | 0.433% | US |
| N/A NATWEST MARKETS PLC 3.53 , 4/01/2026 | — | — — | RA CORP | 41,000 PA | $41.0K | 0.403% | US |
| N/A UMB FINANCIAL CORP. B 3.4 , 4/01/2026 | — | — — | RA CORP | 34,000 PA | $34.0K | 0.334% | US |
| N/A ROYAL BANK OF CANADA 3.45 , 4/01/2026 | — | — — | RA CORP | 17,000 PA | $17.0K | 0.167% | US |
| N/A VPPH_SPSIPH_GOLDMAN | — | — — | DE OTHER | 67 OU | $11.0K | 0.109% | US |
| N/A VPPH_SPSIPH_GOLDMAN | — | — — | DE OTHER | -47 OU | -$684.22 | -0.007% | US |
Positions resolved to the master through ISIN, then rolled up through the taxonomy. 91.1% of reported value reaches a classification.
Percentages are of the reported value of positions above ($10.16M), not of the fund’s net assets ($10.17M). The two differ by cash, derivatives filed with no market value, and rounding.